VIVUS (VVUS) Reports In-Line Q4 Loss of 12c/Share

VIVUS (NASDAQ: VVUS) reported Q4 EPS of ($0.12), in-line with the analyst estimate of ($0.12). Revenue for the quarter came in at $15.34 million versus the consensus estimate of $22.9 million.

Approximately 132,000 and 566,000 Qsymia prescriptions were dispensed in the quarter and year ended December 31, 2015, respectively, compared to 136,000 and 534,000 in the same periods in 2014, respectively.

Business Update

• In December 2015, VIVUS announced the return of the U.S. and Canadian rights for STENDRA from Auxilium Pharmaceuticals, Inc., a subsidiary of Endo Pharmaceuticals, plc, on June 30, 2016, absent an agreement between Auxilium and VIVUS for an earlier termination date.

• In November 2015, VIVUS presented the following posters at Obesity Week 2015.
  • Abstract Title: Effects of Phentermine and Topiramate Extended-Release (PHEN/TPM ER) on Weight Loss (WL) in Patients With a Baseline Body Mass Index (BMI) ≥45 kg/m 2
    Authors: Scott Kahan, MD, MPH; W. Timothy Garvey, MD; Roman Dvorak, MD, PhD
  • Abstract Title: Budget Impact of Phentermine and Topiramate Extended-Release (PHEN/TPM ER) in Patients who are Overweight or Obese With Prediabetes or Type 2 Diabetes Mellitus (T2DM)
    Authors: Sunil Karnawat, PhD; Sarah A. Odeh, BS
  • Abstract Title: Budget Impact Over 2 Years of Treatment With Phentermine and Topiramate Extended-Release (PHEN/TPM ER) in an Overweight/Obese Population
    Authors: Sunil Karnawat, PhD; Sarah A. Odeh, BS

• In October 2015, Mark K. Oki joined VIVUS in the role of Chief Financial Officer and Chief Accounting Officer. Mr. Oki was most recently at Alexza Pharmaceuticals, Inc., a publicly traded pharmaceutical company, where he most recently served as Alexza's Senior Vice President, Finance, Chief Financial Officer, Principal Accounting Officer and Secretary.

For earnings history and earnings-related data on VIVUS (VVUS) click here.

You May Also Be Interested In

• Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
• VIST Financial Corp. (VIST) Misses Q1 EPS by 19c
• Methanex (MEOH) Tops Q1 EPS by 35c